On July 3, SungenBio and Shenyang Pharmaceutical University formally signed a cooperation agreement to develop a new type I biologic nattokinase injection and oral preparation. This project utilizes Shenyang Pharmaceutical University's patent and R & D platform for large molecular protein injections and the research and innovation technology of SungenBio technology, which is expected to solve the development problems of intravenous allergy of protein drugs, etc., and make nattokinase into an oral preparation.